Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Nutex Health (NUTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Nutex Health's Shares Outstanding (Weighted Average) history spans 13 years, with the latest figure at $646.4 million for Q2 2022.

  • For Q2 2022, Shares Outstanding (Weighted Average) rose 9.04% year-over-year to $646.4 million; the TTM value through Jun 2022 reached $646.4 million, up 9.04%, while the annual FY2021 figure was $37.3 million, 655.22% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q2 2022 was $646.4 million at Nutex Health, up from $37.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $646.4 million in Q2 2022 and bottomed at $263269.0 in Q3 2018.
  • The 5-year median for Shares Outstanding (Weighted Average) is $4.8 million (2020), against an average of $95.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) plummeted 99.78% in 2018 before it soared 12647.06% in 2021.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $1.7 million in 2018, then soared by 113.22% to $3.6 million in 2019, then soared by 36.15% to $4.9 million in 2020, then surged by 655.22% to $37.3 million in 2021, then skyrocketed by 1631.73% to $646.4 million in 2022.
  • Per Business Quant, the three most recent readings for NUTX's Shares Outstanding (Weighted Average) are $646.4 million (Q2 2022), $37.3 million (Q4 2021), and $42.4 million (Q3 2021).